HC Wainwright Reiterates “Buy” Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $77.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 313.76% from the company’s previous close.

CAPR has been the subject of several other reports. Oppenheimer restated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Maxim Group raised their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Piper Sandler began coverage on Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 target price on the stock. Finally, Cantor Fitzgerald increased their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Trading Up 0.6 %

NASDAQ:CAPR opened at $18.61 on Thursday. The stock’s 50-day moving average is $15.21 and its 200-day moving average is $8.46. The stock has a market cap of $845.08 million, a P/E ratio of -17.56 and a beta of 4.00. Capricor Therapeutics has a 1-year low of $2.87 and a 1-year high of $23.40.

Insider Transactions at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of Capricor Therapeutics stock in a transaction dated Friday, September 20th. The stock was bought at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 65.21 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares in the last quarter. Renaissance Technologies LLC increased its stake in Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Marshall Wace LLP acquired a new position in Capricor Therapeutics during the second quarter worth $426,000. Rhumbline Advisers acquired a new position in Capricor Therapeutics during the second quarter worth $147,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Capricor Therapeutics in the first quarter valued at $40,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.